Cost-effectiveness analysis of late prophylaxis vs. on-demand treatment for severe haemophilia A in Italy

A. Coppola, A. D'Ausilio, A. Aiello, S. Amoresano, M. Toumi, P. Mathew, A. Tagliaferri, the Potter Study Group, G. Feola, A.C. Molinari, C. Santoro, G.F. Rivolta, D.B. Cultrera, F. Gagliano, E. Zanon, M.E. Mancuso, L. Valdrè, L. Mameli, L. Banov, G. Di MinnoG. Quintavalle, M.G. Mazzucconi, N. Negri, E. Santagostino

Research output: Contribution to journalArticlepeer-review

Original languageEnglish
Pages (from-to)422-429
Number of pages8
Issue number3
Publication statusPublished - 2017


  • recombinant blood clotting factor 8
  • blood clotting factor 8, adolescent
  • adult
  • Article
  • clinical outcome
  • controlled study
  • cost effectiveness analysis
  • disease severity
  • health status
  • hemophilia A
  • human
  • Italy
  • late prophylaxis
  • on demand therapy
  • patient compliance
  • priority journal
  • prophylaxis
  • quality adjusted life year
  • sensitivity analysis
  • therapy
  • cost benefit analysis
  • economics
  • Markov chain
  • quality of life, Cost-Benefit Analysis
  • Factor VIII
  • Hemophilia A
  • Humans
  • Markov Chains
  • Quality of Life

Cite this